Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities (2010 - 2026)

Acadia Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $344.5 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 0.76% year-over-year to $344.5 million; the TTM figure through Mar 2026 stood at $344.5 million (down 0.76% YoY), while the FY2025 annual figure was $317.7 million, down 27.29% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $344.5 million, up from $317.7 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $436.9 million in Q4 2024, with the low at $170.3 million in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $317.7 million (2025), against an average of $302.9 million.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities surged 69.38% in 2023, then retreated 27.29% in 2025.
• Acadia Pharmaceuticals' Total Non-Current Liabilities stood at $178.3 million in 2022, then soared by 69.38% to $302.1 million in 2023, then surged by 44.65% to $436.9 million in 2024, then declined by 27.29% to $317.7 million in 2025, then increased by 8.46% to $344.5 million in 2026.
• Business Quant data shows ACAD's Total Non-Current Liabilities at $344.5 million in Q1 2026, $317.7 million in Q4 2025, and $399.6 million in Q3 2025.